Doing screening tests on patients whose life expectancy is extremely limited because of cancer is not cost-effective, according to a new study published in the Journal of the American Medical Association. The study examined the issue of overtesting in late-stage cancer and raises new questions about overdiagnosis and overtreatment in the healthcare system. Too many tests can raise anxiety in patients and lead to unneeded follow-up tests and treatments that can have serious complications, the study found. Article